Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - NYSE Delayed Price. Currency in USD
1.8100+0.0900 (+5.23%)
At close: 04:00PM EDT
1.8200 +0.01 (+0.55%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7200
Open1.7800
Bid1.8100 x 45900
Ask1.8200 x 45900
Day's Range1.7800 - 1.8700
52 Week Range1.1200 - 3.5200
Volume20,819,933
Avg. Volume21,626,577
Market Cap3.799B
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.6600
Earnings DateNov 14, 2023 - Nov 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.02
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ginkgo Bioworks Holdings, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • PR Newswire

    Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover

    Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Texas A&M University today announced they have been jointly awarded a research grant from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (USDA APHIS) via the National Institute of Food and Agriculture, Agriculture and Food Research Initiative (NIFA AFRI) to study SARS-CoV-2 in white-tailed deer populations in Texas.

  • TipRanks

    ‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $5

    Along with the markets’ recent pullback, so has Cathie Wood’s flagship Ark Innovation ETF (ARKK) handed back some of the year’s prior gains. Nevertheless, it has still outpaced the broader markets this year. And despite growing bearish macro concerns, looking at how Wood expects the landscape to shape up, the ARK Invest CEO is optimistic her innovation-first approach will continue to deliver. “I do think that what’s happening this year is that the market is starting to look over the Fed’s moves…

  • PR Newswire

    Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing

    Ensovi Inc., which has invented an efficient, cell-free biomanufacturing platform that transforms waste CO2 to organic chemicals, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Ensovi will leverage Ginkgo Enzyme Services to help optimize its platform for the cell-free transformation of carbon dioxide (CO2) into Acetyl-CoA, which can then be converted into many other products, such as precursors to f

Advertisement
Advertisement